Orthocell (ASX:OCC) said interim results from a new study showed that nerve repair with the firm's Remplir nerve repair product resulted in superior regeneration of nerve tissue and earlier return of muscle function, compared to the current standard of care, according to a Thursday Australian bourse filing.

The study, commissioned by the firm to support the rollout of Remplir in the US, was evaluating the impact of sutures on nerve regeneration and functional recovery in the surgical repair of severed peripheral nerves.

The use of Remplir allowed surgeons to reduce the number of sutures required to reconnect severed nerves. The study was conducted using an established rat sciatic nerve injury model, and the repair of surgically severed nerves was evaluated in 48 rats across four treatment groups. The first group saw repair using one suture, the second one saw repair using three sutures, the third group saw repair using six sutures, and the fourth saw repair using one suture augmented with Remplir.

Nerve function and regeneration were evaluated up to 12 weeks post-treatment.